Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)

PHASE3CompletedINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

October 31, 2016

Conditions
MetastaticUveal Melanoma
Interventions
DRUG

75mg selumetinib

selumetinib tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.

DRUG

placebo

placebo tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.

DRUG

Dacarbazine

dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle taken in combination with either selumetinib or placebo tablets p.o. twice daily.

Trial Locations (31)

Unknown

Research Site, Los Angeles

Research Site, Aurora

Research Site, Atlanta

Research Site, Lutherville

Research Site, St Louis

Research Site, New York

Research Site, Philadelphia

Research Site, Edegem

Research Site, Ghent

Research Site, Kortrijk

Research Site, Leuven

Research Site, Toronto

Research Site, Montreal

Research Site, Olomouc

Research Site, Prague

Research Site, Hus

Research Site, Nice

Research Site, Paris

Research Site, Heidelberg

Research Site, München

Research Site, Jerusalem

Research Site, Ramat Gan

Research Site, Leiden

Research Site, Barcelona

Research Site, L'Hospitalet de Llobregat

Research Site, Seville

Research Site, Valencia

Research Site, Glasgow

Research Site, Northwood

Research Site, Nottingham

Research Site, Swansea

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY